Priscilla Merriam

Priscilla Merriam practices at Dana-Farber Cancer Institute in Boston, Massachusetts, part of Dana-Farber Cancer Institute.

Priscilla Merriam's NPI, 1407072838, was assigned on April 17, 2007. Priscilla Merriam graduated from Jefferson Medical College of Thomas Jefferson University in 2006. Priscilla Merriam holds Massachusetts license 254182.

Priscilla Merriam's primary practice is Dana-Farber Cancer Institute, at 450 Brookline Avenue, Boston, MA 02115.

Priscilla Merriam's primary practice is Dana-Farber Cancer Institute in Boston, Massachusetts, part of Dana-Farber Cancer Institute. Priscilla Merriam is also affiliated with Massachusetts General Hospital. The medical group on file is Brigham and Women's Hospital. Dmand AI also links Priscilla Merriam to 2 more hospitals and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Priscilla Merriam practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Priscilla Merriam's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Priscilla Merriam's licenses on file in 2 states: Massachusetts and Rhode Island.

CMS data shows 384 Medicare services from Priscilla Merriam across 7 procedure codes in 2024, for 182 Medicare patients. Medicare paid $36,081 for them.

CMS counts 182 Medicare patients who saw Priscilla Merriam in 2024. The largest group is 65 to 74, with 84 patients. 75% of them have high blood pressure, and 71% have high cholesterol. 22% are also on Medicaid. Their average risk score is 2.37, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Priscilla Merriam's median patient age at 66, with 57% women.

In 2024, Priscilla Merriam wrote 89 Medicare Part D claims for 37 patients. 73% of them were for generic drugs. CMS names the drug for 16 of them, across 1 drug with 11 or more claims each, at $22,084 in total drug cost. In 2023, CMS named 51 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Priscilla Merriam for performance year 2024, reported as part of a group. Priscilla Merriam accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Priscilla Merriam as offering telehealth.

Dmand AI links 15 papers to Priscilla Merriam, published from 2011 to 2025. 2013 was the busiest year, with 2. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Leiomyosarcoma and Sarcoma. Priscilla Merriam has published most often in Clin Cancer Res. Priscilla Merriam's most frequent co-authors are Edwin Choy, MD, PhD, George D. Demetri, MD and Gregory M. Cote, MD, PhD.

Dmand AI links Priscilla Merriam to 3 clinical trials, 2 of them phase 2 studies. 2 are still active or recruiting. Conditions studied include Dermatofibrosarcoma, Sarcoma, Alveolar Soft Part and Sarcoma, Clear Cell. National Cancer Institute (NCI) sponsors the most, 3.

CMS Open Payments shows 5 general payments to Priscilla Merriam from 3 drug and device companies from 2017 to 2024. Food and beverage make up the largest share, 100% of the total. Aadi Bioscience, Inc. paid the most, $146.

Priscilla Merriam graduated from Jefferson Medical College of Thomas Jefferson University in 2006.